Bausch + Lomb Corporation (NYSE/TSX: BLCO) has recently announced the appointment of two new members to its board of directors. Effective January 1, 2026, Eduardo C. Alfonso, MD, and Steven H. Collis will join the board, bringing with them a wealth of experience and expertise.
Dr. Eduardo C. Alfonso is a renowned ophthalmologist and an internationally recognized expert in corneal and external eye diseases. His extensive background includes serving as director of the Bascom Palmer Eye Institute and chair of the Department of Ophthalmology at the University of Miami Miller School of Medicine. Dr. Alfonso is known for his significant research and clinical expertise in corneal infections, transplants, and artificial corneas, having authored numerous scientific publications and received major awards from national and international ophthalmology organizations.
Steven H. Collis is best known for his significant leadership role at Cencora, Inc., one of the world’s largest pharmaceutical distribution and healthcare services companies. During his tenure as President and CEO from 2011 to 2024, the company's annual revenue more than tripled, and its global presence expanded significantly through strategic acquisitions and partnerships. Collis currently serves on the board of Elevance Health, a managed healthcare and insurance company.
Following these appointments, Bausch + Lomb's board of directors will now be comprised of 10 members, as a result of changes announced in August 2025. The company's decision to bring Dr. Alfonso and Collis onto the board reflects its commitment to leveraging their expertise to shape the future of the company.
These appointments come as Bausch + Lomb continues to evolve with the changing needs of patients and customers. The company remains dedicated to innovation and improving the standard of care in eye health, offering a wide range of products and devices, from contact lenses to surgical devices, with the goal of turning bold ideas into better outcomes.
As Bausch + Lomb prepares to navigate significant opportunities ahead, the addition of Dr. Alfonso and Collis to the board of directors underscores the company's commitment to accelerating its strategy and leveraging the expertise of industry leaders to drive future growth and success. Today the company's shares have moved -0.94% to a price of $16.82. Check out the company's full 8-K submission here.
